SELECT semaglutide to improve outcomes in patients with obesity and cardiovascular disease, also without diabetes

被引：0
|
作者：
Gajos, Grzegorz [1 ,2 ]
机构：
[1] Jagiellonian Univ Med Coll, Inst Cardiol, Dept Coronary Artery Dis & Heart Failure, Krakow, Poland
[2] St John Paul II Hosp, Krakow, Poland
来源：
CARDIOLOGY JOURNAL | 2024年 / 31卷 / 05期
关键词：
D O I：
10.5603/cj.102158
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：782 / 783
页数：2
相关论文
共 50 条
  • [21] Semaglutide and cardiovascular outcomes by blood pressure in the SELECT trial
    Verma, Subodh
    Deanfield, John
    Arbel, Yaron
    Cariou, Bertrand
    Matos, Ana Laura S. A.
    Hovingh, G. Kees
    Jeppesen, Ole Kleist
    Kahn, Steven
    Latkovskis, Gustavs
    Lingvay, Ildiko
    Maeng, Michael
    Maher, Vincent
    Parkhomenko, Oleksandr
    Poulter, Neil
    van de Borne, Philippe
    Kure, Peter
    Lincoff, Abraham
    CIRCULATION, 2024, 150
  • [22] Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
    Ryan, Donna H.
    Lingvay, Ildiko
    Deanfield, John
    Kahn, Steven E.
    Barros, Eric
    Burguera, Bartolome
    Colhoun, Helen M.
    Cercato, Cintia
    Dicker, Dror
    Horn, Deborah B.
    Hovingh, G. Kees
    Jeppesen, Ole Kleist
    Kokkinos, Alexander
    Lincoff, A. Michael
    Meyhoefer, Sebastian M.
    Oral, Tugce Kalayci
    Plutzky, Jorge
    van Beek, Andre P.
    Wilding, John P. H.
    Kushner, Robert F.
    NATURE MEDICINE, 2024, 30 (07) : 2049 - 2057
  • [23] Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial
    Kahn, Steven E.
    Deanfield, John E.
    Jeppesen, Ole Kleist
    Emerson, Scott S.
    Boesgaard, Trine Wellov
    Colhoun, Helen M.
    Kushner, Robert F.
    Lingvay, Ildiko
    Burguera, Bartolome
    Gajos, Grzegorz
    Horn, Deborah Bade
    Hramiak, Irene M.
    Jastreboff, Ania M.
    Kokkinos, Alexander
    Maeng, Michael
    Matos, Ana Laura S. A.
    Tinahones, Francisco J.
    Lincoff, A. Michael
    Ryan, Donna H.
    DIABETES CARE, 2024, 47 (08)
  • [24] Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
    Husain, Mansoor
    Birkenfeld, Andreas L.
    Donsmark, Morten
    Dungan, Kathleen
    Eliaschewitz, Freddy G.
    Franco, Denise R.
    Jeppesen, Ole K.
    Lingvay, Ildiko
    Mosenzon, Ofri
    Pedersen, Sue D.
    Tack, Cees J.
    Thomsen, Mette
    Vilsboll, Tina
    Warren, Mark L.
    Bain, Stephen C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (09): : 841 - 851
  • [25] Cost-Effectiveness of Semaglutide in Patients With Obesity and Cardiovascular Disease
    Rennert-May, Elissa
    Manns, Braden
    Clement, Fiona
    Spackman, Eldon
    Collister, David
    Sumner, Glen
    Leal, Jenine
    Miller, Robert J. H.
    Chew, Derek S.
    CANADIAN JOURNAL OF CARDIOLOGY, 2025, 41 (01) : 128 - 136
  • [26] The cost-effectiveness of semaglutide in reducing cardiovascular risk among people with overweight and obesity and existing cardiovascular disease, but without diabetes
    Zomer, Ella
    Zhou, Jennifer
    Nelson, Adam J.
    Sumithran, Priya
    Nanayakkara, Shane
    Ball, Jocasta
    Kaye, David
    Liew, Danny
    Nicholls, Stephen J.
    Stub, Dion
    Zoungas, Sophia
    EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES, 2024,
  • [27] Semaglutide for the secondary prevention of cardiovascular disease in people with overweight or obesity, but without diabetes: a cost-effectiveness analysis
    Zomer, E.
    Zhou, J.
    Nelson, A. J.
    Nicholls, S. J.
    Stub, D.
    Zoungas, S.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [28] Semaglutide for the secondary prevention of cardiovascular disease in people with overweight or obesity, but without diabetes: a cost-effectiveness analysis
    Zomer, E.
    Zhou, J.
    Nelson, A. J.
    Nicholls, S. J.
    Stub, D.
    Zoungas, S.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [29] THE COST-EFFECTIVENESS OF SEMAGLUTIDE 2.4MG IN PATIENTS WITH OVERWEIGHT/OBESITY AND CARDIOVASCULAR DISEASE FROM THE SELECT TRIAL
    McEwan, P.
    Bog, M.
    Faurby, M.
    Foos, V
    Lingvay, I
    Lubker, C.
    Miller, R.
    Toliver, J.
    Yeates, F.
    Lincoff, A. M.
    VALUE IN HEALTH, 2024, 27 (06) : S148 - S148
  • [30] SEMAGLUTIDE IMPROVES LIVER ENZYMES AND FATTY LIVER INDEX IN PATIENTS WITH OBESITY AND CARDIOVASCULAR DISEASE - RESULTS FROM THE SELECT TRIAL
    Meyhoefer, Sebastian
    Cariou, Bertrand
    Cercato, Cintia
    Colhoun, Helen
    Deanfield, John
    Kjaer, Mette Skalshoi
    Jeppesen, Ole
    Lincoff, A. Michael
    Lingvay, Ildiko
    Newsome, Phillip
    Nicholls, Stephen
    Pelaez, Maria De Los Angeles Quiroga
    Santini, Ferruccio
    Sanyal, Arun
    Kahn, Steven
    HEPATOLOGY, 2024, 80 : S457 - S459
12345